Mirion Technologies Inc
MIR
ISIN null / Valor 114384757
Mirion Technologies Inc
UMushroom community rating:
About company
Mirion Technologies Inc. is a company specializing in radiation detection, measurement, and monitoring solutions, serving a variety of industrial markets. Established through a series of mergers between 1950 and 2004, Mirion was officially incorporated in 2005 and has since been organized into several key divisions, including Radiation Monitoring, Health Physics, Sensing, Imaging, and Dosimetry Services. The company has expanded its capabilities in the healthcare sector, particularly in occupational dosimetry, medical imaging, nuclear medicine, radiation therapy, and diagnostic imaging quality assurance, leading to the formation of the Mirion Medical group in 2022. Mirion's product offerings are designed to support critical applications in safety, security, and healthcare, providing essential tools for radiation protection and management.
Summarized from source with an LLMView SourceSector: FinanceLatest Results (22.11.2025):
Mirion Technologies Inc reported results for the third quarter of 2025: revenue rose 7.9% to $223.1 million, GAAP net income was $3.1 million (vs. a GAAP loss of $14.0 million year-ago), adjusted EBITDA increased to $52.4 million, and the company reaffirmed most of its 2025 guidance while raising the lower end of its adjusted free cash flow range.
Revenue
Revenue for Q3 2025 was $223.1 million, up 7.9% from $206.8 million in Q3 2024.
Profitability and Adjusted EBITDA
GAAP net income was $3.1 million in Q3 2025 (a 122% improvement vs. a $14.0 million GAAP loss in Q3 2024). Adjusted EBITDA rose 14.7% to $52.4 million (from $45.7 million).
Earnings per Share
GAAP net earnings per share were $0.01 for Q3 2025 (vs. a GAAP loss per share of $0.07 in Q3 2024). Adjusted EPS for the quarter was $0.12 (vs. $0.08 in Q3 2024).
Guidance
Mirion reaffirmed 2025 guidance for total revenue growth (~7.0%–9.0%), organic revenue growth (~4.5%–6.0%), adjusted EBITDA (~$223M–$233M; margin ~24%–25%), and adjusted EPS (~$0.48–$0.52). Guidance assumptions include FX tailwinds and recent acquisitions (Certrec and Oncospace); the announced Paragon acquisition is excluded from 2025 guidance.
Adjusted Free Cash Flow Update
The company raised the lower end of its 2025 adjusted free cash flow guidance to $100M–$115M (previously $95M–$115M), implying adjusted FCF conversion of ~45%–49% of adjusted EBITDA (previously 43%–49%).
Acquisitions and Nuclear Power Exposure
Mirion noted the July closing of Certrec and announced an agreement to acquire Paragon Energy Solutions (deal not included in 2025 guidance). Management expects nuclear power–based revenue to be ~45% of total after these transactions.
Large Opportunity Pipeline and Orders
As part of a previously disclosed $350M large opportunity pipeline, Mirion won an ~ $10M small modular reactor new-build order in Q3 2025 and an ~ $55M Asia installed-base order in October 2025. Approximately $285M of the pipeline remains, with ~$175M expected to be awarded in 2025 and ~$110M now expected in 2026 due to timing.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
5836 M
Market cap (USD)
4,006,434
Daily traded volume (Shares)
17.64 / 17.25
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
